Preferred Label : Oncolytic Vaccinia Virus Expressing Anti-CD19/CD3 Bispecific Antibody RGV004;
NCIt synonyms : CD19/CD3 Bispecific Antibody-expressing Oncolytic Vaccinia Virus RGV004; Oncolytic Vaccinia Virus RGV004;
NCIt definition : A genetically-engineered vaccinia virus (VV) encoding a bispecific antibody specific
for the tumor-associated antigen (TAA) CD19 and the T-cell surface antigen CD3, with
potential oncolytic, immunostimulating and antineoplastic activities. Upon administration,
the oncolytic VV expressing anti-CD19/CD3 bispecific antibody RGV004 specifically
infects and replicates in tumor cells causing viral-mediated tumor cell lysis. The
released virus particles, in turn, infect and replicate in neighboring tumor cells.
Tumor antigens released from the lysed tumor cells also activate the immune system
to induce a tumor-specific cytotoxic T-lymphocyte (CTL)-mediated immune response,
thereby killing nearby non-infected tumor cells. In addition, RGV004 promotes the
secretion of the anti-CD19/CD3 bispecific antibody by the infected tumor cells. The
bispecific antibody targets and binds to both the CD3 on T-cells and the CD19 antigen
expressed on tumor cells. This results in the cross-linking of T-cells and tumor cells
and may induce a CTL-mediated immune response against CD19-expressing tumor cells.
CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.;
Molecule name : RGV 004; RGV-004;
NCI Metathesaurus CUI : CL1663329;
Origin ID : C180686;
UMLS CUI : C5556559;
Semantic type(s)
- Virus [UMLS semantic type]
- concept_is_in_subset
- has_target
